An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs.
about
Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.A Helix-Stabilizing Linker Improves Subcutaneous Bioavailability of a Helical Peptide Independent of Linker Lipophilicity.Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results.
P2860
An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs.
@en
An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs.
@nl
type
label
An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs.
@en
An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs.
@nl
prefLabel
An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs.
@en
An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs.
@nl
P2860
P1476
An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs.
@en
P2860
P2888
P304
P356
10.1007/S00280-013-2289-4
P577
2013-09-22T00:00:00Z